Northern Ont. motorcyclists cruise 1,000 miles for Leukemia & Lymphoma Society
More than a dozen motorcycle enthusiasts from Greater Sudbury took off for a long journey Friday morning.
They're part of the 1000-Mile Ride Challenge for the Leukemia & Lymphoma Society of Canada.
It's the first event of its kind and was organized by Dave and Crystal Beauparlant. Dave was diagnosed with leukemia in December 2023.
He said his health is day-to-day, but he wanted to combine his love of motorcycles with a cause close to his heart.
'A thousand-mile ride is not an easy challenge, but cancer at the end of the day gets in the way of anything,' said Dave. 'There's not much awareness out there for leukemia. And being in northern Ontario, I find there's not enough compared to the big cities… This is why we're doing it to Thunder Bay and back.'
The group left from The Rock Harley Davidson dealership Friday, where Dave's son, Ben works.
1000-mile ride
More than a dozen motorcycle enthusiasts from Greater Sudbury took off from The Rock Harley Davidson dealership on Long Lake Road in Greater Sudbury, Ont., on July 11, 2025 to begin a 1,000 mile ride in support of the Leukemia & Lymphoma Society of Canada. (Angela Gemmill/CTV News Northern Ontario)
They plan to drive to the Terry Fox Memorial in Thunder Bay and then return to Sault Ste. Marie early Saturday morning. The entire 1,000 miles is estimated to take about 18 hours.
Ben predicted the journey would be tough, speaking with CTV News on Friday.
'It's going to be hard, but no matter what, we're going to do it. We're going to come out on top,' he said. 'Being up for that amount of time and being on the bike - two wheels especially, you've got to keep your balance. So, it's going to be rough on the body, but you just got to keep positive.'
There is help available just in case – a chase truck stocked with snacks, drinks and Gerry cans of fuel in case some of the smaller gas tanks run dry.
Dave's cousin Steve Beauparlant volunteered to drive that chase truck.
'It's nice that I can be here able to support and even if I can't ride a bike, well, it doesn't mean I can't be there with the truck and fuel and everything else,' Steve said.
According to Dave this first-ever event has been able to raise more than $14,000 for the Leukemia & Lymphoma Society of Canada. The Beauparlant family hopes it becomes an annual event for the north.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
36 minutes ago
- National Post
Residents at Villa Colombo Face Dangerous Negligence from Replacement Workers as Strike Continues
Article content TORONTO — The members of CUPE Local 5525 have been on strike since May 28 th, after rejecting an offer filled with concessions that attack their benefits, and the sick days they need to provide safe and respectful care to their clients. The employer, Villa Colombo Home for the Aged, hired replacement (scab) workers to do the work of the members of 5525 while they are striking. After weeks of mistreatment and neglect, the residents and family members of Villa Colombo are speaking out. Article content The members of CUPE 5525, many of whom have over a decade of service in this community, have deep, trusting relationships with these residents and caring for them in their home. These residents have lived in this community for years, and all require some level of personal care to maintain their independence and live their golden years in dignity. The residents have been complaining that the replacement workers show up late, don't perform the needed tasks, and in some cases, much worse. Article content Article content The residents are tired of Villa Colombo driving down the quality of their care to try and punish the members of 5525 for forming a union. Several residents and their family members are prepared to tell their stories to the media, to ensure the word gets out that all is not well in their community. Article content The Union and residents of Villa Colombo, call on Villa Colombo Homes for the Aged, as well as the parent organization Villa Charities, to immediately stop using replacement scab labour that is putting seniors at risk, and return to the bargaining table with a meaningful offer on Sick Days and a benefits package that reflects the value the members of 5525 bring to the community. Article content Article content Article content Article content Article content Article content
National Post
an hour ago
- National Post
Market to Grow by 12.1% to Reach $6.97 Billion this Year - Investment Opportunities to 2029
Article content DUBLIN — The 'Canada Diabetes Devices and Therapeutics Market Investment Opportunities – Q2 2025 Update' report has been added to offering. Article content The diabetes market in Canada is expected to grow by 12.1% on annual basis to reach US$6.97 billion in 2025. The diabetes market in the country has experienced robust growth during 2020-2024, achieving a CAGR of 12.9%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 10.0% during 2025-2029. By the end of 2029, the diabetes market is projected to expand from its 2024 value of USD 6.22 billion to approximately USD 11.37 billion. Article content This report provides a detailed data-centric analysis of the diabetes industry in Canada, covering market opportunities and analysis across a range of diagnosis and monitoring devices, therapeutics, domains. With over 50+ KPIs at the country level, this report provides a comprehensive understanding of diabetes market dynamics, market size and forecast, and market share statistics. Article content The diabetes devices and therapeutics market in Canada comprises established multinational firms and emerging domestic players. A structured healthcare system with defined reimbursement pathways supports traditional and digital solutions. The Canadian diabetes devices and therapeutics market is characterized by a blend of multinational leaders and emerging technology-driven entrants. Recent strategic partnerships, mergers, and acquisitions indicate a move toward more integrated care solutions. In the coming years, competitive dynamics are expected to intensify, driven by consolidation and a focused shift toward digital integration and regulatory compliance. Article content The Canadian market is experiencing significant shifts, with increased CGM adoption, digital integration, advanced therapeutic systems, and evolving regulatory support. These trends will intensify over the next 2-4 years, shaping clinical practices and reimbursement structures across provincial healthcare systems. Article content Expand Continuous Glucose Monitoring Usage Article content Canadian healthcare systems are broadening the use of continuous glucose monitoring (CGM) devices across several provinces. Provincial pilot programs in regions such as Ontario and British Columbia are incorporating CGM into routine diabetes care. Adjustments in provincial reimbursement policies and recent clinical studies from Canadian health agencies support wider CGM use. Recent publications have highlighted a shift in clinical practice toward data-driven patient monitoring. The adoption of CGM is expected to intensify as more provinces expand coverage and integrate real-time data into care protocols. Enhanced patient monitoring may improve diabetes management outcomes over the medium term. Article content Digital health platforms that support remote monitoring and telemedicine are increasingly integrated into diabetes management in Canada. Several regional healthcare systems have initiated digital dashboards to consolidate patient data for clinical decision-making. Government initiatives to improve telehealth services and recent shifts in healthcare delivery models are driving digital integration. Recent publications underscore provincial health ministries' investments in digital infrastructure. The integration of digital tools is projected to grow, supporting real-time care adjustments and enhanced data sharing among providers. This trend is expected to intensify as digital health reshapes chronic disease management. Article content Advance Therapeutic Delivery Systems Article content Advanced therapeutic devices such as smart insulin pens and connected insulin pumps are being tested in clinical settings across Canada. Pilot programs in select provinces have assessed these devices for precise dosing and improved treatment adherence. Recent technological improvements and research findings from Canadian institutions support the development of these systems. Funding and innovation incentives from provincial health programs are fostering the introduction of these therapeutic tools. Adoption will likely grow as clinical evidence and reimbursement models evolve, integrating these devices into standard practice. The trend is expected to intensify gradually, influencing treatment protocols in diabetes care. Article content Regulatory and Reimbursement Models Article content Regulatory bodies in Canada are updating guidelines and reimbursement policies to accommodate new diabetes devices and therapeutics. Recent policy documents have outlined pathways for including digital health and connected devices in public healthcare programs. Broader cost-containment strategies and ongoing evaluations of digital health effectiveness drive regulatory adjustments. Publications from provincial health ministries and Health Canada provide context for these evolving frameworks. Clearer regulatory and reimbursement models are anticipated to further support device integration and market expansion. These changes are expected to have a progressive impact, offering more defined channels for innovation in diabetes management. Article content Key Competitors and New Entrants Article content Several longstanding multinational companies hold significant market share. They offer a range of devices, from continuous monitoring systems to therapeutic delivery tools, and maintain strategic relationships with provincial healthcare agencies. New market entrants, including technology-focused startups, are introducing digital health solutions that target remote monitoring and data integration. Recent publications indicate that pilot programs in provinces allow these entrants to demonstrate value. Article content Recent publications detail partnerships where established companies collaborate with digital health startups to enhance device connectivity and patient data analytics. Mergers and acquisitions have been noted as firms consolidate technical expertise and broaden their market offerings within the Canadian context. These strategic developments reshape the market by promoting integrated care solutions and streamlined regulatory compliance. Collaborative efforts are aligning product innovation with provincial healthcare priorities. Article content Future Competitive Dynamics (2-4 Years) Article content The competitive landscape is expected to evolve as strategic partnerships and consolidation efforts deepen. Companies will likely increase investments in digital health integration, balancing established market leaders with nimble entrants. Over the next 2-4 years, market consolidation and technology-driven innovation are anticipated to further define competitive positioning, with clear implications for patient management strategies. Article content Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices Article content Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices Article content Self-Monitoring Blood Glucose Devices Continuous Blood Glucose Monitoring Devices Test Strips Lancets Article content Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices Article content Insulin Pumps Insulin Pens Insulin Syringes Article content Diabetes Devices and Therapeutics Market Share by Therapeutics Article content Oral Anti-Diabetic Drugs Insulin Non-Insulin Injectable Drugs Combination Drugs Article content Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs Article content Alpha-Glucosidase Inhibitors DPP-4 Inhibitors SGLT-2 Inhibitors Article content Diabetes Devices and Therapeutics Market Share by Insulin Article content Basal or Long-Acting Bolus or Fast-Acting Traditional Human Insulin Drugs Insulin Biosimilars Article content Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs Article content GLP-1 Receptor Agonists Amylin Analogue Article content Diabetes Devices and Therapeutics Market Share by Combination Drugs Article content Combination Insulin Oral Combination Article content Diabetes Devices and Therapeutics Market Share by Route of Administration Article content Subcutaneous Intravenous Others Article content Diabetes Devices and Therapeutics Market Share by Type of Diabetes Article content Type 1 Diabetes Type 2 Diabetes Article content Diabetes Devices and Therapeutics Market Share by Distribution Channels Article content Online Pharmacies Hospital Pharmacies Retail Pharmacies Article content Diabetes Devices and Therapeutics Market Share by End User Article content Hospitals Diabetes Clinics Homecare Article content Key Attributes: Article content Report Attribute Details No. of Pages 50 Forecast Period 2025 – 2029 Estimated Market Value (USD) in 2025 $7.77 Billion Forecasted Market Value (USD) by 2029 $11.37 Billion Compound Annual Growth Rate 10.0% Regions Covered Canada Article content For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Article content Article content Article content Article content Article content Contacts Article content Article content
CTV News
an hour ago
- CTV News
More salami recalled amid Salmonella outbreak
Rea's sweet soppressata salami joins the latest recalls linked to an outbreak of Salmonella infections. (Handout) The Canadian Food Inspection Agency (CFIA) has issued a recall for Rea's sweet soppressata salami due to possible salmonella contamination. The affected product is identified by its Universal Product Code 841571 042200. Consumers are urged to check for affected products and dispose of or return any items matching the listed UPC immediately. The latest recall comes on the heels of a salmonella outbreak tied to pork deli meats sold at grocery stores and in prepared sandwiches. The Public Health Agency of Canada (PHAC) said the infections are linked to Rea brand Genoa Salami Sweet, Rea brand Genoa Salami Hot and Bona brand Mild Genova Salam - which was recalled by the CFIA on June 10 in three provinces. Since April, 84 people have gotten sick and there have now been nine hospitalizations, according to the PHAC. As of July 11, 67 people are sickened in Alberta, 15 people in Ontario and one person in Manitoba. One illness reported in B.C. is related to travel to Alberta. What is Salmonella? Salmonella is a food-borne bacterial illness that can spread several days or weeks after a person is infected, even if they don't have symptoms. According to the CFIA, healthy people may experience short-term symptoms such as fever, headache, vomiting, nausea, abdominal cramps and diarrhea. Severe arthritis is a possibility in long-term complications, it added. Salmonella-contaminated food may not look or smell spoiled but can still cause illness, it warned. The CFIA says most people who become ill from a salmonella infection can recover fully after a few days without treatment, while in other cases it can cause severe illness and hospitalization. What you should do Consumers are urged to check product labels and UPC codes against CFIA's alerts. The health agency also advises consumers to not consume any recalled items or food containing them and discard or return affected items to the place of purchase.
